ONWARD Medical

ONWARD Medical operates at the intersection of spinal cord injury therapeutics, implantable neuromodulation, and brain-computer interfaces. Its differentiation is the breadth of its ARC Therapy platform: ARC-EX provides external, non-invasive stimulation for hand function, ARC-IM is an investigational implantable system targeting movement and autonomic functions, and ARC BCI combines movement-intention decoding with spinal stimulation. The company therefore spans both a commercially available device and higher-risk clinical programs, rather than competing solely in rehabilitation equipment or solely in implanted neurotechnology. ONWARD’s strongest demonstrated advantage is regulatory and commercial progression: ARC-EX is FDA cleared in the United States and CE marked under the EU Medical Device Regulation, while the company reported 117 systems sold during its 2025 US launch. Its focus on spinal cord injury gives it a narrower therapeutic scope than broad digital-health or general neurostimulation companies, but also supports a coherent product architecture and specialized clinical network. The principal market question is whether early commercial adoption can support the expensive clinical development required for ARC-IM and ARC BCI.

ONWARD Medical’s growth trajectory is defined by a sequence of financing, regulatory, and commercialization inflection points. Founded in 2014, the company raised $31.9 million in a 2021 venture round and went public on Oct 21, 2021, with an IPO valuation of approximately $441.8 million. Capital formation accelerated after listing: the company completed a $21.9 million post-IPO equity round in March 2024, a $56.3 million post-IPO debt financing in June 2024, a $54.1 million equity financing in October 2024, and a $58.1 million equity financing in October 2025. The additional $47.8 million raised in April 2026 extends funding for commercialization and pipeline execution. Commercially, ARC-EX moved from FDA authorization and an initial US rollout in 2025 to 117 systems sold during that year, followed by broader clinic and home-use availability reported on Sep 9, 2026. At the same time, ARC-IM advanced through first-in-human lumbar-lead use and the Empower BP pivotal study pathway. The trajectory is therefore shifting from technology proof and regulatory access toward revenue generation, while clinical programs remain the main source of execution risk.